Orphan Technologies, a Lexington, Mass.-based subsidiary of Petach Tikva-based Neopharm Group, said that it completed a study showing that the prevalence of the rare genetic metabolic disorder homocystinuria (HCU) is substantially higher than previously estimated. The company is developing OT-58, a modified recombinant enzyme therapy for patients with classical HCU.